This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pabinger, I. Articles by Ay, C. Search for Related Content PubMed PubMed Citation Articles by Pabinger, I. Articles by Ay, C. Related Collections Venous Thromboembolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:332.)
© 2009 American Heart Association, Inc.

Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness

Biomarkers and Venous Thromboembolism

Ingrid Pabinger; Cihan Ay

From the Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria.

Correspondence to Prof Dr Ingrid Pabinger, Professor of Hemostaseology, Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail ingrid.pabinger{at}meduniwien.ac.at

Venous thromboembolism (VTE) represents a significant health concern because of its high morbidity and mortality and is moreover characterized by high rates of recurrence. It would be useful to know biomarkers that enable early identification of patients at high or low risk of primary and recurrent VTE. Various established and novel biomarkers associated with VTE have been investigated with regard to their potential for predicting primary or recurrent VTE, for facilitating the diagnosis and for optimizing the clinical management of VTE. In this review, data on selected biomarkers (D-Dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers and thrombin generation) having procoagulant properties or reflecting a prothrombotic state are summarized, and their role in clinical application is discussed.

Key Words: venous thromboembolism • recurrence • biomarker • D-Dimer • P-selectin

This article has been cited by other articles:

				K. Devreese, K. Peerlinck, and M. F. Hoylaerts Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants Blood, January 28, 2010; 115(4): 870 - 878. [Abstract] [Full Text] [PDF]

				A. S. Wolberg and N. Mackman Venous Thromboembolism: Risk Factors, Biomarkers, and Treatment Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 296 - 297. [Full Text] [PDF]